Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma

Binod Dhakal(Medical College of Wisconsin), Mehdi Hamadani(Medical College of Wisconsin), Parameswaran Hari(Medical College of Wisconsin), Anita D’Souza, Lauren Veltri(West Virginia University), Daniel Eastwood(Medical College of Wisconsin), Jean Esselman(Medical College of Wisconsin), Abraham S. Kanate(HonorHealth), Timothy S. Fenske(Medical College of Wisconsin), Michael Craig(Edith Cowan University), Aaron Cumpston(West Virginia University Hospitals), Marcelo C. Pasquini(Cleveland Clinic), Alexandra Shillingburg(West Virginia University)
Transplantation and Cellular Therapy
June 27, 2016
10.1016/j.bbmt.2016.06.016
Cited by 8

Related Papers

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
|Transplantation and Cellular Therapy|2020|718